<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; responsible</title>
	<atom:link href="http://www.tapanray.in/tag/responsible/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>OTC Drugs in India: ‘Where Art Thou?’</title>
		<link>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=otc-drugs-in-india-where-art-thou</link>
		<comments>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/#comments</comments>
		<pubDate>Mon, 02 Sep 2019 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advertisement]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[classification]]></category>
		<category><![CDATA[D&C]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[juggernaut]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[non-prescription]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[Over The Counter]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[rule]]></category>
		<category><![CDATA[schedule K]]></category>
		<category><![CDATA[self-medication]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US_FDA]]></category>
		<category><![CDATA[Where Art Thou]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9692</guid>
		<description><![CDATA[It is now a widely accepted fact that responsible self-medication plays an important role in health care, facilitating greater access to medicines and reducing overall health care cost. With continued improvement in people&#8217;s education, general knowledge and socioeconomic conditions, self-medication has &#8230; <a href="http://www.tapanray.in/otc-drugs-in-india-where-art-thou/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An El Dorado&#8230;But Not Without Responsible Pricing:The Cancer Segment in India</title>
		<link>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area</link>
		<comments>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/#comments</comments>
		<pubDate>Mon, 04 Feb 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[British]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cervical]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[oral]]></category>
		<category><![CDATA[ovarian]]></category>
		<category><![CDATA[ovary]]></category>
		<category><![CDATA[pancreatic]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[pot]]></category>
		<category><![CDATA[pots]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1493</guid>
		<description><![CDATA[The affordability issue for cancer treatment has been the subject of a raging debate since quite some time, as the incidence of cancer is fast increasing across the world. Just for example a very recent report highlighted that cancer has now become the &#8230; <a href="http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Conundrum of Stringent IPR Regime in India: Responsible Pricing still remains ‘The Final Frontier’</title>
		<link>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier</link>
		<comments>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/#comments</comments>
		<pubDate>Mon, 26 Nov 2012 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[final]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[stringent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1063</guid>
		<description><![CDATA[In his management classic named, ‘The Practice of management’, published in 1954, the universal management guru Peter Drucker postulated that any successful business is driven by only the following two fundamental functions: Marketing Innovation …and all the rests are costs. &#8230; <a href="http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
